Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe by Jacqueline Kerr et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 12 December 2014
doi: 10.3389/fimmu.2014.00629
Is dosing of therapeutic immunoglobulins optimal?
A review of a three-decade long debate in Europe
Jacqueline Kerr 1, Isabella Quinti 2, Martha Eibl 3, Helen Chapel 4, Peter J. Späth5,W. A. Carrock Sewell 6,
Abdulgabar Salama7, Ivo N. van Schaik 8,TacoW. Kuijpers9 and Hans-Hartmut Peter 10*
1 Section Poly- and Monoclonal Antibodies, Paul Ehrlich Institut, Langen, Germany
2 Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
3 Immunologische Tagesklinik, Vienna, Austria
4 Nuffield Department of Medicine, University of Oxford, Oxford, UK
5 Institute of Pharmacology, University of Bern, Bern, Switzerland
6 Hull York Medical School, University of Lincoln, Lincoln, UK
7 Zentrum für Transfusionsmedizin u. Zelltherapie, Charité, Berlin, Germany
8 Department of Neurology, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands
9 Department of Pediatric Hematology, Immunology and Infectious disease, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands
10 Centrum für chronische Immunodeficienz (CCI), University Medical Centre, University of Freiburg, Freiburg im Breisgau, Germany
Edited by:
Albert Farrugia, University of Western
Australia, Australia
Reviewed by:
Antonio Condino-Neto, University of
São Paulo, Brazil
Alessandro Plebani, University of
Brescia, Italy
*Correspondence:
Hans-Hartmut Peter , Centrum für
chronische Immundefizienz (CCI),
Engesserstr. 4, D-79108 Freiburg im
Breisgau, Germany
e-mail: hans-hartmut.peter@
uniklinik-freiburg.de
The consumption of immunoglobulins (Ig) is increasing due to better recognition of antibody
deficiencies, an aging population, and new indications. This review aims to examine the
various dosing regimens and research developments in the established and in some of the
relevant off-label indications in Europe. The background to the current regulatory settings
in Europe is provided as a backdrop for the latest developments in primary and secondary
immunodeficiencies and in immunomodulatory indications. In these heterogeneous areas,
clinical trials encompassing different routes of administration, varying intervals, and infusion
rates are paving the way toward more individualized therapy regimens. In primary antibody
deficiencies, adjustments in dosing and intervals will depend on the clinical presentation,
effective IgG trough levels and IgG metabolism. Ideally, individual pharmacokinetic pro-
files in conjunction with the clinical phenotype could lead to highly tailored treatment.
In practice, incremental dosage increases are necessary to titrate the optimal dose for
more severely ill patients. Higher intravenous doses in these patients also have benefi-
cial immunomodulatory effects beyond mere IgG replacement. Better understanding of
the pharmacokinetics of Ig therapy is leading to a move away from simplistic “per kg”
dosing. Defective antibody production is common in many secondary immunodeficien-
cies irrespective of whether the causative factor was lymphoid malignancies (established
indications), certain autoimmune disorders, immunosuppressive agents, or biologics. This
antibody failure, as shown by test immunization, may be amenable to treatment with
replacement Ig therapy. In certain immunomodulatory settings [e.g., idiopathic thrombo-
cytopenic purpura (ITP)], selection of patients for Ig therapy may be enhanced by relevant
biomarkers in order to exclude non-responders and thus obtain higher response rates. In
this review, the developments in dosing of therapeutic immunoglobulins have been limited
to high and some medium priority indications such as ITP, Kawasaki’ disease, Guillain–Barré
syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis,
multifocal motor neuropathy, fetal alloimmune thrombocytopenia, fetal hemolytic anemia,
and dermatological diseases.
Keywords: IVIG, SCIG, replacement therapy, immunomodulation, dosing
INTRODUCTION
Indications for intravenous (IVIG) and subcutaneous (SCIG)
immunoglobulin (Ig) therapies are steadily increasing and the
annual demand has tripled in the last 15 years reaching a world-
wide consumption of ~130 metric tons in 2012 (1). Shortages in
supply have occurred in the past and cost pressure on health sys-
tems worldwide is growing The increased demand for therapeutic
Ig has been met by increasing the number of plasma donors and
by introducing new high-yield fractionation procedures, which
in some cases have been accompanied by increases in rates of
hemolytic anemia.
Reports involving alternative doses given in both Ig replace-
ment and immunomodulatory indications are questioning cur-
rent practice. These, together with emerging biomarkers associated
with Ig-responder and non-responder status, invite close scrutiny
of indications for, and methods of administering, IVIG and SCIG
use in the future. Traditional dosing of Ig has relied heavily
on a “per kg of bodyweight” calculation, which has now been
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Table 1 | Well established indications according to “Guideline to assess efficacy and safety of normal intravenous immunoglobulin products”
(CPMP/388/95 and CPMP/BPWG/859/95).
1994 “well established” indications Dose Frequency of injections
REPLACEMENTTHERAPY IN
Primary immunodeficiency syndromes (PID)
• Congenital agammaglobulinemia and hypogammaglobulinemia
• Common variable immunodeficiency disorders
• Severe combined immunodeficiencies
•Wiskott–Aldrich syndrome
Starting dose: 0.4–
0.8 g/kg – thereafter:
0.2–0.8 g/kg
0.2–0.4 g/kg
Every 3–4 weeks to obtain IgG trough level of at least
5–6 g/l
Every 3–4 weeks to obtain IgG trough level of at least
5–6 g/l
Secondary immunodeficiency syndromes (SID)
•Myeloma 0.2–0.4 g/kg
• Chronic lymphocytic leukemia (CLL) with severe secondary
hypogammaglobulinemia and recurrent infections
• Congenital AIDS with recurrent infections
0.2–0.4 g/kg Every 3–4 weeks
Every 3–4 weeks to obtain IgG trough level of at least
5 g/l
IMMUNOMODULATORY EFFECT IN
• Idiopathic thrombocytopenic purpura (ITP) in adults and children
at high risk of bleeding or prior to surgery to correct platelet count
0.8–1 g/kg or
0.4 g/kg/day
On day 1, possibly repeated once within 3 days
• Kawasaki disease 0.4 g/kg/day For 2–5 days
• Bone marrow transplantation (BMT) 1.6–2 or 2 g/kg For 5 days in divided doses over 2–5 days in
association with acetylsalicylic acid in one dose in
association with acetylsalicylic acid
brought into question [Ref. (2) and Chapel, submitted]. Given
that IVIG/SCIG is manufactured from a limited resource, the pos-
sibility of dose adjustment according to lean body weight or even
fixed doses titrated to effect in both replacement therapy and in
immunomodulation arises (2, 3). This may become especially rele-
vant in view of the combination of increasing numbers of patients
due to improving diagnostics in developing countries, an aging
population, and worldwide increases in body weight.
In this situation, the authors felt a need to reconsider the dos-
ing issue for the so-called established indications (Table 1) by
reviewing the literature, addressing safety and efficacy issues of
new IVIG and SCIG preparations, and proposing appropriate
measures where needed. The issue of class effect of different Ig
preparations will be discussed. To date, switching brands during
shortages or because of tender systems does not seem to have had
clinically relevant effects on efficacy. However, the spectrum of
side effects may differ from brand to brand, according to route of
application, infusion rates, different dose levels, and the underly-
ing disorder. In addition, product switching complicates exposure
tracking in the event of a contamination incident, and alters the
donor exposure profile of individual patients. Thus, dosing rec-
ommendations might have to be adjusted for certain diseases on
the basis of effectiveness, safety profiles, and possibly in future on
the basis of validated individual biomarkers and clinical outcome.
Switching from IVIG to SCIG in the case of chronic disor-
ders has been the topic of recent research given similar efficacy to
IVIG infusions, the lower incidence of systemic side effects, a lack
of “wear-off” effect, improved health-related quality of life, better
treatment satisfaction, and faster functional recovery with less time
off work are frequently quoted advantages of SCIG (4, 5). The pos-
sible pharmacoeconomic benefits of SCIG are beyond the scope
of this review, especially considering the various health/insurance
systems and the varying prices of SCIG and IVIG in the different
European countries. In general, switching from IVIG to SCIG in
Europe is done in a dose-equivalent manner and not performed
with a dose adjustment coefficient (DAC) as applied in the USA
(~150%) (6, 7). As no official guidelines require a DAC in Europe
(coreSPC, see below) additional product costs do not incur. The
efficacy of DAC vs. dose-equivalent switch is a matter of ongoing
debate and may require more long-term data.
As all authors of this review build on a long-standing pro-
fessional experience in Europe, the current dosing recommenda-
tions reflect European practice, which has grown historically and
encompasses recommendations from learned societies, national
recommendations, European recommendations (8), and the Euro-
pean Medicines Agency (EMA). In the next section, the regulatory
framework and the historical development of the EU recommen-
dations will be briefly outlined without elaborating on subtle
differences to American, Canadian, and Australian guidelines.
REGULATORY FRAMEWORK
Three main bodies regulate blood products in Europe:
• the European Directorate for the Quality of Medicines and
Healthcare (EDQM), which provides standardization of quality
control of medicines as elaborated in the European Pharma-
copeia; it also co-ordinates the network of the Official Medicines
Control Laboratories (OMCL),
• the EMA, which evaluates marketing authorization or vari-
ation applications for medicinal products within the EU in
the so-called centralized procedure (CP); it composes Inves-
tigational Guidelines for clinical trials and core Summary of
Product Characteristics (coreSPCs), i.e., templates for Product
Information leaflets), and
• the Heads of Medicines Agencies (HMA), which is network of
the heads of the National Competent Authorities (NCA) whose
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organizations are responsible for the regulation of medicinal
products for human use in the European economic area (EEA)
in so-called mutual recognition (MR) or decentralized (DC)
Procedures.
In 1994, the criteria for investigating IVIG in clinical trials
were laid out in the “Guideline to assess efficacy and safety of
normal intravenous immunoglobulin products” (CPMP/388/95)
and a core Summary of Product Characteristics (coreSPC;
CPMP/BPWG/859/95) encompassing “well established” indica-
tions for IVIG was proposed (see Table 1). These“well established”
indications were based on certain pivotal studies and the doses
administered therein; they became the cornerstone for the dosing
recommendations in the coreSPC.
In 2000, analogous documents (investigational Guideline
and coreSPC) were devised for subcutaneous and intramus-
cular immunoglobulin products (CPMP/BPWG/283/00 and
CPMP/BPWG/282/00).
Over the years, these documents have undergone a number
of revisions in order to encompass the developments in medical
research and practice.
The current European Investigational Guideline and core-
SPC for IVIG are undergoing a revision process (for Concept
Paper see: http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2014/08/WC500170555.pdf )
The revision of Investigational Guideline and the coreSPC
for SCIG is near completion: http://www.ema.europa.eu/docs/en_
GB/document_library/Scientific_guideline/2012/12/WC5001357
05.pdf and http://www.ema.europa.eu/docs/en_GB/document_
library/Scientific_guideline/2012/07/WC500130466.pdf
In the EU three IVIG and two SCIG preparations have been
centrally authorized (CP procedure)1 and five IVIG and two
SCIG brands were granted authorization via the MR- or DC-
procedures2. In addition, some European countries will have
nationally authorized products.
Several National Guidelines consider neuroimmunological dis-
eases such as Guillain–Barré syndrome (GBS), chronic inflam-
matory demyelinating polyneuropathy (CIDP), multifocal motor
neuropathy (MMN), myasthenia gravis (MG), and others as
high to medium priority immunomodulatory indications for
IVIG/SCIG use [Ref. (8); supporting information Table 2].
Progress in this field will be discussed as well as changing high-
priority indications in pediatric AIDS, feto-neonatal alloimmune
thrombocytopenia (FNAIT), and dermatological indications.
Owing to space limitations the majority of the medium
and low-priority indications [Ref. (8); supporting information
Table 2] were not included in this review.
REPLACEMENT THERAPY
PRIMARY IMMUNODEFICIENCY SYNDROMES (PID)
In 1952, Colonel Ogden Bruton (9) noted the absence of serum Ig
in an 8-year-old boy with a history of pneumonia and other bacte-
rial sino-pulmonary infections. Bruton was also the first physician
1http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_
search.jsp&mid=WC0b01ac058001d124
2http://mri.medagencies.org/Human/
Table 2 | Abbreviations used in the text.
BMT Bone marrow transplantation
BPWP Blood products working party
BWP Biologics working party
CHMP Committee for medicinal products for human use
CIDP Chronic inflammatory demyelinating
polyradiculoneuropathy
CLL Chronic lymphocytic leukemia
CMD-human Co-ordination group for MR- and DC-procedures
CMS Concerned member states
CMV Cytomegalovirus
CoE Council of Europe
coreSPCs Core summaries of product characteristics
CP Centralized procedure
DCP Decentralized procedure
EDQM European Directorate for the Quality of Medicines and
Healthcare
EEA European economic area
EMA European medicines agency
EU European union
FNAIT Fetal neonatal alloimmune thrombocytopenia
GBS Guillain–Barré syndrome
GvHD Graft vs. host disease
HMA Heads of medicines agencies
HSCT Hematopoietic stem cell transplantation
ITP Idiopathic thrombocytopenic purpura
IVIG Intravenous immunoglobulin
KD Kawasaki’s disease
MM Multiple myeloma
MMN Multifocal motor neuropathy
MRP Mutual recognition procedure
NCA National competent authorities
OMCL Official medicines control laboratories
PE Plasma exchange
PAD Primary antibody deficiency
PID Primary immunodeficiency syndromes
PK Pharmacokinetic
PRAC Pharmacovigilance risk assessment committee
RMS Reference member state
RBC Red blood cell
SBI Severe bacterial Infections
SCIG Subcutaneous immunoglobulin
SID Secondary immunodeficiency syndromes
to provide specific immunotherapy for this X-linked disorder by
initially administering 3.2 g of IgG subcutaneously. Assuming an
approximate weight of an 8-year old to be 30 kg, this dose would
correspond to 0.1 g/kg. This dosing was taken into the coreSPC,
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but is currently considered within the low range of the recom-
mended weekly dosing for SCIGs (0.1 g/kg–0.2 g/kg/week) or the
monthly dosing of IVIG (0.4 g/kg–0.8 g/kg/month).
Current IVIG coreSPC indication and dosing:
Primary immunodeficiency syndromes with impaired antibody production
The recommended starting dose is 0.4–0.8 g/kg given once, followed by at
least 0.2 g/kg given every 3–4 weeks.
The dose required to achieve a trough level of 5–6 g/l is of the order of
0.2–0.8 g/kg/month. The dosage interval when steady state has been
reached varies from 3-4 weeks. Trough levels should be measured and
assessed in conjunction with the incidence of infection. To reduce the rate
of infections, it may be necessary to increase the dosage and aim for
higher trough levels.
Current draft SCIG coreSPC indication and dosing:
Primary immunodeficiency syndromes with impaired antibody production
The dose regimen should achieve a trough level of IgG (measured before
the next infusion) of at least 5-6 g/l and aim to be within the reference
interval of serum IgG for age. A loading dose of at least 0.2-0.5 g/kg (10-40
ml/kg) body weight may be required. This may need to be divided over
several days, with a maximal daily dose of 0.1-0.15 g/kg)
After steady state IgG levels have been attained, maintenance doses are
administered at repeated intervals (approximately once per week) to reach
a cumulative monthly dose of the order of 0.4-0.8 g/kg. Each single dose
may need to be injected at different anatomic sites.
Trough levelsa should be measured and assessed in conjunction with the
incidence of infection. To reduce the rate of infection, it may be necessary
to increase the dose and aim for higher trough levels.
aN.b:Trough levels can be measured for a facilitated SCIG given every 3-4 weeks
and for a normal SCIG given at biweekly-weekly intervals; however, in clinical
practice SCIG products are sometimes given at even shorter intervals - in these
cases the term "trough level" would not capture the fact that what is actually being
measured is the mean level.
Recent developments in Ig replacement therapy of PID
The demonstrated success of Ig prophylaxis via the intravenous
route depends predominantly on maintaining an adequate pro-
tection against infections. According to international guidelines
the Ig monthly dose of 300–600 mg/kg body weight should be
administer intravenously every 3 or 4 weeks and subcutaneously
once/twice a week (10–13). The trend over the past years has been
to increase the monthly cumulative doses (14–17). This general
rule might not be optimal for all patients affected by primary
antibody deficiencies (PAD) due to high clinical and immuno-
logical heterogeneity of the underlying diseases. A recent paper
(18) analyzed the clinical presentation, association between clini-
cal features, and differences and effects of Ig treatment in a large
series of European patients affected by common variable immun-
odeficiency disorders (CVID), the most common symptomatic
PAD. Different treatment strategies applied in Europe resulted
in considerable differences in Ig dosing, ranging from 0.13 up
to 0.75 g/kg/month. This and previous studies suggested that a
correlation between patients’ antibody levels and clinical effects:
patients with very low-trough levels of <4 g/l had poor clinical
outcomes (15, 16, 19) whereas higher trough levels were associated
with a reduced frequency of serious bacterial infections.
Thus, the aim should be to maintain an individual’s effec-
tive antibody level and not to establish a universally defined
immunoglobulin monthly dosage. Consequently, almost all recent
studies on Ig replacement advocate that the treatment strategies
should be individualized not only in terms of dosages but also
with regard to treatment schedules including intervals between
administrations and routes of administration (20–23). Milito et al.
(24) have recently demonstrated that in PAD patients with fewer
disease-associated complications the IVIG replacement could be
administered with the widely used interval of 3 or 4 weeks, even
administering low-IVIG replacement dosages. On the other hand,
in patients with bronchiectasis and enteropathy and a severe
immunological phenotype with IgG trough levels<500 mg/dl, IgA
<7 mg/dl, absent response to polysaccharides, and low-switched
memory B cells (<2%) the protective effect might be achieved
by lowering the interval between administrations to 2 weeks
and in few cases to 1 week, without increasing the cumulative
monthly Ig dosage (19). Alternatively, patients with severe clin-
ical and immunological phenotypes might be treated with higher
Ig dosages at an interval of 3–4 weeks. The need to elucidate the
effects of therapy on patient outcomes might allow identification
of what works best in which setting and under what conditions (25,
26). Health care delivery systems are quickly changing in response
to economic pressure and concerns about quality of care emerge.
The system of care is itself an important determinant of patient
outcomes. The promise of individualized medicine has launched
a huge research enterprise to explore the personal characteristics
that influence responses to therapy.
The pharmacokinetics (PK) of IgG and specific antibodies
exhibited a different half-life in patients treated at different inter-
vals between infusions (26). Trough levels of the lowest specific
antibody concentrations rise if regular infusions are given and the
actual trough levels in a regularly infused patient are likely to be
higher than the levels of specific IgG measured by ELISA in the
IVIG preparations (27, 28).
The clinical relevance of regular application of Ig has been
underlined by the finding that an important determinant of the
efficacy of Ig prophylaxis is the length of time an individual
spends with a lower IgG level a situation, which is minimized
by subcutaneous therapy (29). This time is more dependent on
the patient’s IgG half-life and the frequency of dosing than on
the dose of Ig infused. In clinical practice, it would be ideal to
perform a PK study in all patients. However, this would require
a significant commitment in time and costs from the patient
and the treating physician. This practical drawback has limited
the use of PK information in clinical practice. Different alter-
native options have been attempted. The Oxford approach, for
example, based on monitoring break-through infections, was to
increase the IVIG dose by 0.15 g/kg/month when patients present
with a serious infection, or three or more moderate infections
over a year (17). This recommendation could be an alternative
for patients who have persistent infections; although other fac-
tors such as protein loosing conditions, airway and intestinal
inflammation, need to be assessed when defining an individual
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Ig treatment schedule as the Oxford approach related treatment to
CVID phenotype (17). Moreover, in PAD, several lines of experi-
mental evidence gathered recently (30–32) provided a basis for an
active role for IVIG in immunomodulation beside the main role
to replace the missing antibodies. Ig has such a role in regulating
autoimmune and inflammatory responses through modulating B
and other cells functions (8). These new findings might help to
explain the different results found in trials aimed at establishing
the clinical outcome of Ig replacement in PAD patients. It is pos-
sible that some of the positive effects observed in patients treated
with higher doses are not dependent only on the prophylactic
role of Igs but also on their anti-inflammatory ones. In con-
trast to subcutaneous administration, intravenous administration
might allow maintenance of the protective and immunomodula-
tory effects due to the serum IgG peak reached at the time of each
administration.
Methods to improve IgG recovery and increase productivity
have been implemented in the last few years as a response to grow-
ing clinical demand for therapeutic Igs (27). Any effects of major
changes in the Ig production should be assessed in clinical and
drug surveillance studies.
In addition, approval has been granted for
• high-concentration formulations of IVIG and SCIG prepara-
tions (27, 29, 33),
• rapid push administration (34),
• one SCIG product (Hyqvia) combined with the prior use of a
spreading factor (hyaluronidase), thus, allowing for 3–4 weekly
intervals (current indication excludes children<18 years) (35)3,
and
• one SCIG product (Hizentra) where modeling and simulation
approaches were applied that led to comparable IgG exposure
levels if the product were to be administered every 2 weeks using
double the weekly dose during maintenance therapy (21, 22)4.
SCIG studies in PID
A recent evidence-based review article (36), comparing IVIG and
SCIG administration in PID and SID patients, encompassed 25
studies (in PID patients 2/25 studies were randomized and 17 non-
randomized; for SID patients 1/25 studies was non-randomized
and 5/25 were health economic studies). Of the studies that men-
tioned specific products, eight used an SCIG from CSL-Behring,
seven a product from Baxter, and two a product from Grifols.
Only 3/25 studies reported severe bacterial infections (SBI) as
their primary outcome of interest for both SCIG and IVIG; no
SBI occurred in these studies. In a total of five studies, the annual
number of infections was investigated and no difference found
between the two routes of administration; however, the definitions
of infections were fairly heterogeneous. Higher IgG trough levels
were found with SCIG substitution. No serious adverse events
were reported in five trials that investigated this parameter, how-
ever, here again definitions and inclusion/exclusion criteria varied.
3http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/002491/human_med_001647.jsp&mid=WC0b01ac058001d124
4http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/
medicines/002127/human_med_001440.jsp&mid=WC0b01ac058001d124
Minor adverse events, consisting of local symptoms were usu-
ally mild and more frequent with SCIG substitution, as would
be expected of this modality. Four studies investigating health-
related quality of life showed improvement when patients switched
from hospital-based IVIG to SCIG substitution at home. Of the
5/25 studies that evaluated health economics, 4 found that SCIG
administration was considerably more cost effective in compari-
son with IVIG substitution, whereas one older study did not show
this gain.
The authors caution the reader that for most efficacy and safety
parameters measured in the studies the value of evidence was low
and that with regard to the pharmacoeconomic evaluation due to
the differences in the health care and insurance systems in the dif-
ferent countries the results cannot be generalized. They conclude
that good studies comparing IVIG to SCIG are lacking, but it is
possible to state that SCIG is safe and efficacious and at least non-
inferior to IVIG. They also view the issue of switching from IVIG
to SCIG as not yet solved.
SECONDARY IMMUNODEFICIENCY SYNDROMES (SID)
Patients with secondary immunodeficiency are a continuously
increasing heterogeneous group (36, 37). Recommendations for
treatment of antibody deficiency associated with lymphoid malig-
nancies [e.g., CLL, multiple myeloma (MM)], post-hematopoietic
stem cell transplantation (HSCT), or HIV are referred to in core
SPCs, which require critical updates. Those SIDs due to med-
ications [e.g., anticonvulsants, anti-rheumatics, MAbs (e.g., anti-
CD20), chemotherapy, immunosuppression] may be suspected
from the patient’s medical history although usually only a subset
of patients develops signs of SID.
SID patients are often less well defined than PADs as the diag-
nosis relies only on serum Ig levels rather than proven antibody
failure, but their clinical importance is recognized increasingly.
In this section, findings in patient groups, including those not
included in the core SPC, are discussed.
Patients with SID are unduly susceptible to different types of
pathogens depending on the type of SID: viral and/or oppor-
tunistic infections are common in patients with non-functional
or absent T-cells while bacterial infections predominate in anti-
body failure syndromes. Severe life-threatening infections affect
the respiratory or gastrointestinal tracts though chronic infections
of prolonged duration also occur with agents of low pathogenic-
ity (38, 39). These infections are an important cause of morbidity,
mortality, hospital admissions, and intensive care treatment in this
group of patients. The following discussion relates largely to anti-
body failures secondary to therapy or disease that maybe amenable
to treatment with Ig replacement therapy.
Numerous studies in patients with lymphoid malignancies
have shown beneficial effects of IVIG, resulting in fewer infec-
tious episodes, reduced use of antibiotics, shorter hospital stay but
no difference in overall mortality. Most of these studies report
on patients in chronic state of disease, treated with IVIG doses
comparable to patients with PAD.
Chronic lymphocytic leukemia (CLL)
In 1988, the Cooperative Group for the Study of Immunoglobulin
in CLL published the results of a double-blind, placebo-controlled
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study (40) in 81 CLL patients (with 50% lower than normal
IgG levels and a history of >1 serious infection since onset
of the illness). Those patients who received immunoglobulin
therapy (0.4 g/kg every 3 weeks for ~1 year) had significantly fewer
bacterial infections compared to those in the placebo group.
Current IVIG coreSPC indication and dosing:
Hypogammaglobulinaemia and recurrent bacterial infections in patients
with CLL, in whom prophylactic antibiotics have failed.
The recommended dose is 0.2–0.4 g/kg every 3–4 weeks.
Current draft SCIG coreSPC indication and dosing:
Hypogammaglobulinaemia and recurrent bacterial infections in patients
with CLL, in whom prophylactic antibiotics have failed or are
contra-indicated.
For dosing see PID/SCIG above.
Following the original multi-center, randomized, placebo-
controlled study (40) that resulted in inclusion in the coreSPC,
the protective effect of IVIG in CLL and low-grade non-Hodgkin’s
lymphoma was confirmed by a 2 year, placebo vs. Ig cross-over
study (41); in this study, serious bacterial infections correlated
with low-serum IgG levels (<6.4 g/l) (41). Along the same line
Boughton et al. (42) noted that 10 patients (24%) with IgG levels
<3.0 g/l experienced 65% of infections in the whole CLL group.
In view of newer treatments for CLL, studies on frequencies of
bacterial infections before and after treatment with fludarabine,
anti-CD20, or BTK inhibitors will be important. Such studies need
to include documentation of IgG levels and specific antibody titers
following test immunization.
Antibody deficiency, for which hypogammaglobulinemia is a
surrogate, is the most important risk factor for bacterial infections;
furthermore, antibody failure, as shown by test immunization, can
occur in the absence of hypogammaglobulinemia (43). Failure to
respond to test immunization with approved, killed vaccines is the
most reliable indicator though absence of circulating antibodies
after documented infections, such as HSV or VZV, are also help-
ful. Test immunizations in CLL patients have shown poor IgG
responses against a range of antigens, including polysaccharide
vaccines or conjugate pneumococcal vaccines (44). Whether those
patients that do produce antibodies are even protected against
bacterial infections is not clear due to lack of clinical trials (45).
At present most guidelines use serum IgG levels in SID but logic
requires test immunizations of patients (one protein and one poly-
saccharide vaccine) rather than relying on previous infections or
surrogate markers.
Data from the original trials (40, 41) showed that starting doses
of IVIG used in PAD (0.4 g/kg/month) were protective against
bacterial infections in patients with low-serum IgG levels. Protec-
tion at a lower dose of IVIG (0.3 g/kg/month) was confirmed by
Molica et al. (46) in a cross-over study in which 42 patients with
serum IgG levels<6 g/l and/or a history of severe infection received
either IVIG (0.3 g/kg/month) or standard care for 12 months and
then crossed over to the alternative regime. Jurlander et al. (47)
showed that 15 patients with low-serum IgG receiving 10 g IVIG
every 3 weeks (0.2 g/kg/month) had reduced hospital admissions
for infections and significantly reduced febrile episodes although
neither were totally abolished.
Multiple myeloma (MM)
In 1994, Chapel et al. published a study on IVIG as a prophylaxis
in 83 patients with stable MM (48). As in the case of CLL, the
administration of IVIG (0.4 g/kg every 4 weeks for 1 year) led to
significant reduction in life-threatening infections compared to
placebo.
Current IVIG coreSPC indication and dosing:
Hypogammaglobulinaemia and recurrent bacterial infections in plateau
phase MM patients who have failed to respond to pneumococcal
immunization.
The recommended dose is 0.2–0.4 g/kg every 3–4 weeks.
Current draft SCIG coreSPC indication and dosing:
Hypogammaglobulinaemia and recurrent bacterial infections in MM
patients
For dosing see PID/SCIG above.
The randomized placebo-controlled multi-center study in
plateau-phase MM patients given IVIG 0.4 g/kg monthly for
1 year showed significant reductions in frequency and severity
of infections (48). Fortunately, this trial included test immuniza-
tion with polysaccharide pneumococcal vaccine before starting
Ig therapy and benefit from IVIG was shown only in patients
who responded poorly to pneumococcal immunization and had
normal numbers of circulating neutrophils (48). Recently, anti-
body failure to a range of pathogens in MM and related con-
ditions has been confirmed (49) suggesting that IVIG therapy
may be justified. However, many newer treatment regimes in MM
use antibiotic prophylaxis and each patient should be consid-
ered primarily on an individual basis for Ig therapy until more
data is provided. Similar conclusions were drawn from a recent
systemic review and meta-analysis by Raanani et al. (50) sug-
gesting that IVIG cannot be recommended routinely for patients
with CLL or MM with hypogammaglobulinemia and/or recur-
rent infections; instead decisions should be made on an individual
basis.
Bone marrow transplantation
In 1990, Sullivan et al. (51) published the results of a double blind,
placebo-controlled study in 382 bone marrow transplant recip-
ients. The patients received placebo or 0.5 g/kg IVIG from day
−7 to day +90, and continued IVIG treatment on a monthly
basis until 1 year after transplantation. The endpoints were the
rate of interstitial pneumonia and acute Graft vs. Host Disease
(GvHD). Among the 61 cytomegalovirus (CMV) seronegative
patients, none contracted interstitial pneumonia and in the group
of 308 CMV positive patients the IVIG treated ones fared signifi-
cantly better. Acute GvHD was reduced in the IVIG treated patients
over 20 years of age but not in the younger age group.
In the initial coreSPC, the indication covered both GvHD and
infection prophylaxis (mainly for CMV infection) and was thus
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placed in the category of immunomodulation. However, a later
placebo-controlled, double-blind study by Cordonnier et al. (52)
and a meta-analysis on 30 trials including 4223 patients (53)
revealed that there was no benefit on survival and frequency of
infections while the risk of veno-occlusive disease (VOD) was
increased. Thus, after allogeneic HSCT IVIG is currently used as a
replacement therapy for hypogammaglobulinaemic patients with
secondary B cell deficiency (serum IgG< 4 g/l) and no longer for
GvHD.
The use of SCIG compared to IVIG has been studied in one
non-randomized, retrospective study in 58 children with pro-
longed hypogammaglobulinemia after HSCT. All children were
treated with IVIG and 12 continued on SCIG home treatment
(54). While being of equivalent efficacy to IVIG, SCIG showed
fewer side-effects and was the preferred treatment option.
Current IVIG coreSPC indication and dosing:
Hypogammaglobulinaemia in patients after allogeneic haematopoietic
stem cell transplantation (HSCT).
The recommended dose is 0.2–0.4 g/kg every 3–4 weeks.
Hypogammaglobulinaemia in patients requiring allogeneic hematopoietic
stem cell transplantation (HSCT).
For dosing see PID/SCIG above.
Congenital AIDS
In the late 1980s, the US National Institute of Child Health
and Human Development (NICHHD) performed a double blind,
placebo-controlled, multi-center IVIG study in 372 children with
symptomatic HIV infection (55). The children were given 0.4 g/kg
every 4 weeks. Median follow-up time was 17 months. The results
showed that for children with CD4+ T-cell entry values >200/ml
the time free of serious bacterial infection increased, serious and
minor infections were reduced, as were the number of hospital-
izations. However, there was no survival advantage for the IVIG
group.
A further double blind, placebo-controlled IVIG study in 255
children with AIDS was published in 1994 (56). All children had
received 180 mg/m2 of zidovudine. The IVIG dose was 0.4 g/kg
every 4 weeks. Patients were stratified according to their history
(>1 serious bacterial infection), previous zidovudine treatment,
and trimethoprim–sulfamethoxazole (TMP–SMZ) prophylaxis
for Pneumocystis jirovecii pneumonia at entry. Median follow-
up time was 30.6 months. The children who were on IVIG
plus zidovudine and not receiving TMP–SMZ prophylaxis had
a reduced rate of serious bacterial infections. As currently an effi-
cient, highly active anti-retroviral therapy (HAART) is given to the
mothers prior to delivery the development of congenital AIDS and
pediatric HIV associated antibody deficiency is greatly reduced.
In these patients, IVIG treatment is medically necessary for the
prevention of bacterial infection when the following criteria are
met (A) diagnosis of HIV disease, (B) patient age ≤13 years, and
(C1) documented hypogammaglobulinemia or (C2) functional
antibody deficiency as demonstrated by pool specific anti-titers
(or recurrent bacterial infections). IVIG dose should not exceed
1.4 g/kg every 28 days. IVIG replacement therapy in HIV infected
children without antibody deficiency may not be necessary; indeed
it is even contra-indicated in the UK Guidelines.
Current IVIG coreSPC indication and dosing:
Congenital AIDS with antibody deficiency and recurrent bacterial infections.
The recommended dose is 0.2-0.4 g/kg every three to four weeks.
No current SCIG coreSPC indication or dosing under discussion.
Recent developments in Ig replacement therapy of SID
After anti-CD20 therapy. Anti-CD20 trials, however, have moni-
tored both circulating B cells and serum Igs and although originally
reduction of serum Igs was thought to be transient, some patients
continue to have hypogammglobulinaemia and accompanying
infections for prolonged periods possibly forever (57). In this
recent study from Sloan-Kettering involving patients with lym-
phoid malignancies, low-serum IgG levels were identified in 38.5%
(69/179) of patients after CD20 therapy, all of whom had normal
levels initially; the risk was greater in patients who received main-
tenance rituximab. In 14 patients of this subset, IVIG significantly
reduced the frequency of sino-pulmonary bacterial infection and
pneumonias (57). Likewise, monitoring serum IgG levels and B cell
numbers after anti-CD20 treatment in ANCA+ vasculitis is war-
ranted for recognition of SID (58, 59), which may require IVIG
replacement therapy.
After immunosuppressive regimes in solid organ transplanta-
tion. Floruesco et al. (60) discuss the impact of hypogamma-
globulinemia on the rate of infections and survival following
solid organ transplantation, in a meta-analysis that included 1756
patients from 18 studies. The study included patients with lung,
kidney, heart, and liver transplants. The rate of severe hypogam-
maglobulinemia (IgG< 0.4 g/dl) amounted to 15%; it signifi-
cantly increased the risk of CMV, fungal, and respiratory infections
and was associated with higher 1-year all-cause mortality as orig-
inally described by Rubin (61). Sarmiento et al. (62) looked at 75
patients post heart transplantation of whom 10 patients developed
CMV disease; those with a low-serum IgG level (IgG< 5 g/dl) were
at higher risk of reactivation of CMV disease; the authors recom-
mended CMV monitoring as a potential tool to recognize high-risk
patients (62). More recently, Carbone et al. (63) reported results
from 55 consecutive adult heart recipients who were subjected to
an immune monitoring including measurement of specific anti-
bodies and underwent IVIG therapy when SID was established.
Eighty five percent of severe infections occurred during the first
3 months and mean time to IVIG infusion was 2.47 months. IVIG
therapy resulted in improved specific antibody titers in the group
on replacement therapy and a significant reduction of bacterial
infections, in the substituted group of patients compared with 55
untreated patients.
During autoimmune diseases. An increased risk of invasive
pneumococcal disease has been demonstrated in a retrospective
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analysis of a cohort of systemic autoimmune diseases includ-
ing patients with SLE, rheumatoid arthritis, hemolytic anemia,
and Sjogren’s syndrome (37–39, 64). In a 10-year European study
of 1000 SLE patients 68 patients died (6.8%) and the most fre-
quent causes of death were similarly divided among active SLE
(26.5%), thrombosis (26.5%), and infections (25%), especially
in the first 5 years after diagnosis (65). Similar results have been
obtained in a multi-ethnic US cohort study: the 5-year mortality
was 11.8%, active SLE (41%), and fatal infections (32%) headed
the ranking (66). Infections were also frequent causes of increased
hospitalization (67). Prolonged hypogammaglobulinemia requir-
ing antibody replacement therapy occurred in 21% of ANCA+
vasculitis patients treated with cyclophosphamide followed by
rituximab (58).
Antibody failure due tomedications other than immunosuppres-
sants. It has been known for a long time that anticonvulsant
therapy with phenytoin or carbamazepine can cause low-serum
IgG levels and recurrent infections (68, 69). Recently, valproic acid,
a histone deacetylase (HDAC) inhibitor, has also been demon-
strated to inhibit early B cell differentiation and activation (70)
leading to hypogammaglobulinemia. Few studies performed in
small patient groups with SID due to immunosuppressive med-
ication or chemotherapy also demonstrate beneficial effects of
IVIG treatment. However, robust studies looking on clinical out-
come are lacking, not least as prophylactic antibiotics are used as
standard measure in many centers.
Most studies in SID conditions such as CLL, MM, solid organ
transplantation, and autoimmune diseases have been performed
in chronic, stable disease with 0.3–0.4 g/kg IVIG every 3–4 weeks.
Outcome in patients with antibody deficiency, with or without
low-serum IgG levels as well as episodes of severe – potentially
lethal – infection have to be included in the analysis (37–39).
Present research in translational medicine including PID aims at
early diagnosis to identify patients before the first (potentially life
threatening) infectious complications and this applies to SID as
well. Further clinical trials have been recommended in patients
with SID. Patient selection in such studies will be critical and only
test-immunized patients with proven antibody deficiency should
be entered (one T dependent vaccine – usually tetanus toxoid is
used since the assay is reliable and available in immunology lab-
oratories and one T-independent vaccine – either pneumovax or
polysaccharide Salmonella vaccine – both with reliable assays as
used in PIDs). IVIG should be given early on during the course of
an aggressive immunosuppressive therapy since lethal infections
often occur at this stage.
IMMUNOMODULATORY THERAPY
IDIOPATHIC THROMBOCYTOPENIC PURPURA
In 1981, Paul Imbach and colleagues (71) treated 13 children with
idiopathic thrombocytopenic purpura (ITP) (6 with acute and
7 with chronic forms of ITP, platelets counts <30,000/µl) with
0.4 g/kg/day IVIG for 5 days and could demonstrate a normal-
ization of platelets counts (150–600× 103/µl) in 12/13 children
within 5 days. However, the effect was transient as platelets fell to
80–400× 103/µl during the following 10 days.
In the years after this study, various trials followed in adults with
ITP – also comparing IVIG to prednisone. In a study by Blanchette
et al. (72), a reduced dose of 0.8–1.0 g/kg was given on day 1. If 48–
72 h later platelet counts remained at values≤20× 103/µl a second
IVIG dose was recommended. Although this protocol proved to
be equally efficacious as the original of Imbach et al. (70), it was
the latter one that set the stage for the regulatory adoption of the
dosage regimen in ITP and other “immunomodulatory settings”
for years to come.
In 2009, the International Working Group (73) standardized
the terminology, definitions, and outcome criteria for clinical tri-
als in ITP, which in turn was taken on board during the IVIG
guideline and coreSPC revision process.
Current IVIG coreSPC indication and dosing:
Primary immune thrombocytopenia (ITP), in patients at high risk of
bleeding or prior to surgery to correct the platelet count.
There are two alternative treatment schedules:
0.8–1 g/kg given on day one; this dose may be repeated once within 3 days
0.4 g/kg given daily for 2–5 days.
The treatment can be repeated if relapse occurs.
No current SCIG coreSPC indication or dosing under discussion.
Recent developments in ITP research
Treatment options in ITP vary with patient age (childhood vs.
adults) and diagnostic status (newly diagnosed, persistent for
3–12 months, chronic beyond 12 months, or secondary to other
diseases) (74, 75). Notably, in newly diagnosed ITP of childhood
(<18 years) the standard of care is still IVIG at a total dose of 0.8–
1.0/kg given on 1 or 2 consecutive days. In IVIG non-responders,
the results can be improved by adding 20 mg/kg methylpred-
nisolone during day 1–3 (75). In a prospective randomized trial,
a 2 g/kg total dose IVIG was clearly more effective than 50 or
75µg/kg anti-D as first-line treatment in childhood ITP (76).
Interestingly, individual cases of successful treatment with very
low-IVIG doses (100 or 200 mg/kg) imposed by economic con-
straints have been reported (77, 78). These observations warrant a
systematic evaluation of an up-scaling protocol starting with doses
of 0.2–0.4 g/kg IVIG. In a study from Thailand (a developing coun-
try), cost effectiveness of IVIG in childhood ITP has been proven,
as compared to standard treatment of thrombocyte transfusions,
corticosteroids plus immunosuppressants (79). On the other hand,
health economic studies from Canada and Ireland show for adult
chronic ITP patients that romiplostim, a thrombopoietin recep-
tor agonist, seems to compare favorably with standard treatment
including IVIG (80, 81).
A general observation throughout all ITP studies is an IVIG
response rate of 60–75% in newly diagnosed childhood ITP. Hope-
fully, new biomarkers may in future be able to identify early on
IVIG responders from non-responders. Thus, a recent study by
Morimoto et al. (82) indicates that patients with WBC count
<7.0× 109/l had a lower probability of thrombocytopenia-free
survival (41 vs. 77%, P = 0.003) and a higher rate of progression
Frontiers in Immunology | Primary Immunodeficiencies December 2014 | Volume 5 | Article 629 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kerr et al. Dosing therapeutic immunoglobulins
to chronic ITP (29 vs. 6%, P = 0.040) than those with WBC count
≥7.0× 109/l. These results suggest that ITP with lower WBC count
may represent a distinct subgroup requiring early on additional
or other treatments than IVIG [e.g., rituximab (83)]. Similarly,
in adults with ITP, the presence of anti-GPIb-IX auto-antibodies
is a predictor for poor response to IVIG treatment: only 36.4%
responded as compared to 80% of anti-GPIb-IX negative ITP
patients (84). Less promising results came from studies correlating
FcγRIIa and FcγRIIIa polymorphic variants to IVIG responsive-
ness and outcome (85): while the high-affinity FcγRIIIa variant
158V is possibly implicated in the pathogenesis of ITP, FcγRIIa
(131R), and FcγRIIIA (158V) variants do not seem to impact on
chronicity and therapeutic efficacy of IVIG, although studies on
such correlations are underway. In this respect, it is interesting that
the expression of an open-reading frame for the activating FcγRIIc
(instead of the more common, non-expressed pseudogene) also
seems to predispose to ITP (86).
KAWASAKI DISEASE
Kawasaki disease (KD) is an acute self-limiting inflammatory
disorder of children, associated with vasculitis, affecting predom-
inantly medium-sized arteries, particularly the coronary arteries.
In 1984, Furusho et al. (87) treated 93 patients with KD [45
with acetylsalicylic acid (ASA) and 40 with ASA+ IVIG] at a
dose of 0.4 g/kg/day for 5 day. They observed a greater percentage
of patients with coronary artery lesions in the ASA-alone group
compared to the combined therapy (42 vs. 15%).
In 1991, Newburger et al. (88) treated 276 KD patients with
ASA and IVIG 0.4 g/kg/day for 4 day vs. 273 ASA+ IVIG 2 g/kg
(given once). The rational to choose 2 g/kg (and not 1.6 g/kg) for
the single dose was that serum IgG concentration on day 4 of the
0.4 g/kg× 4 day regime would be approximately the same. It was
shown that the single large dose was more effective than the con-
ventional regimen and equally safe. Both dosing possibilities were
taken into the coreSPC (0.4 g/kg/day IVIG for 5 day+ASA and
IVIG 2 g/kg+ASA).
Current IVIG coreSPC indication and dosing:
Kawasaki disease.
2.0 g/kg as a single dose is the recommended treatment worldwide.
Patients should receive concomitant treatment with acetylsalicylic acid.
No current SCIG coreSPC indication or dosing under discussion.
Recent developments in KD research
The etiology of KD is still unknown. It is assumed that uniden-
tified infectious agents trigger a strong, self-limiting inflamma-
tion in genetically susceptible hosts. Numerous studies have been
undertaken to identify susceptibility genes for KD as well as for
resistance to IVIG treatment. Polymorphic variants of FCGR2A,
CD40, ITPKC, FAM167A-BLK, and CASP3 have been shown to
be associated with KD (89). Similarly, gene copy number (GCN)
variants of FcγR2c and FcγR3b were significantly associated with
KD susceptibility and seem to influence also the IVIG treatment
response (90) as does the increased expression of IL-1 pathway
genes (91). Recently,Ogata et al. (92) found that sialylation levels of
therapeutic IVIG are unrelated to treatment response whereas low
sialylation of endogenous IgG and low-serum β-galactoside:α2-6
sialyltransferase-I (ST6Gal-I), ST6GAL1 RNA, and enzyme levels
predict therapy resistance. As the authors compare only 10 IVIG
responders to 10 non-responders their findings have to be met
with great caution and need a rigorous confirmation.
The analysis of 3860 data sets from children with KD registered
in the Taiwan National Health Insurance Data Base focused on the
impact of different IVIG manufacturing procedures on the respon-
siveness in KD (93). They compared effects of β-propiolactone,
acidification,and IgA content. Whereasβ-propiolactone treatment
of Ig had a relative risk of 1.45 to confer IVIG non-responsiveness
and prolonged anti-platelet and anti-coagulants treatment, the rel-
ative risks for acidification and IgA content were non-significant in
this respect. These findings are difficult to confirm as IVIG treated
with β-propiolactone is no longer on the market.
On clinical grounds IVIG non-responders were shown to be
older, had >6 days fever before the initiation of IVIG therapy;
their serum levels of CRP, total bilirubin, lactate dehydrogenase
(LDH), and gamma-glutamyltranspeptidase (g-GT) were signif-
icantly higher (P = 0.002, P < 0.001, P < 0.034, and P < 0.038,
respectively), and their hemoglobin value was significantly lower
(P = 0.025) than in IVIG responders (94–96). The authors defined
the following predictors for IVIG non-responders: CRP level
>10 mg/l, LDH level>590 IU/l, and/or hemoglobin value<10 g/l
and suggested as escalating treatment options corticosteroids (97),
TNF blockers (89, 98, 99), or plasma exchange (100).
Until relatively recently, corticosteroids were considered poten-
tially detrimental in KD, as early studies showed an association
with worse outcome (101). However, it is likely that this at least in
part reflected an inadvertent selection bias, as those with more
severe KD received corticosteroids. Corticosteroids are recom-
mended as “rescue” therapy if there is no response to initial
infusion(s) of IVIG (102). More recently, the potential role of cor-
ticosteroids as adjunct primary therapy in addition to IVIG has
been addressed in randomized trials, either in unselected patients
or in those considered at particularly high risk of coronary artery
damage.
A multicenter, randomized, double-blind trial from the U.S.
assessed primary treatment with IVIG (2 g/kg) and aspirin with or
without a single dose methylprednisolone (30 mg/kg) in 199 uns-
elected children. Addition of a single steroid dose to conventional
therapy did not improve coronary artery outcomes (103).
A more recent prospective randomized, open-label, trial in
Japan enrolled only those assessed by a locally derived risk score as
being at particularly high risk of coronary damage (104). Patients
were randomized to a prolonged course of intravenous followed
by oral prednisolone (or placebo), in addition to standard ther-
apy with IVIG (2 g/kg) and aspirin. Coronary artery outcomes
during the 4-week study period were significantly better in the
corticosteroid group. However, the generalizability of these find-
ings is uncertain; in particular, the scoring system on which
selective recruitment was based does not perform well in non-
Japanese patients (105, 106). As approximately three-quarters of
KD patients were excluded, as they did not meet enrollment crite-
ria [including those with coronary artery dilatation at presentation
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(104)], it remains unclear whether this corticosteroid regimen
would benefit KD patients more broadly. Moreover, the prolonged
intravenous course of corticosteroids would itself incur signifi-
cant additional costs by prolonged admission and potential side
effects (105).
GUILLAIN–BARRÉ SYNDROME
In the late 1990s, the indication GBS was taken on board the
coreSPC as a new “established indication” after a prior authoriza-
tion of a product specific indication within a variation procedure.
The variation procedure showed that the data were mainly based
on three published studies which each used different Ig prod-
ucts but revealed similarly efficacious outcomes with regard to
decrease in disability grading when compared to plasma-exchange
(PE) – the standard therapy at the time (107–109). In the stud-
ies by van der Meché (107) and the GBS Trial Group (109),
the dosing was 0.4 g/kg× 5 day and in the study by Bril et al.
(108) 0.5 g/kg× 4 day. The dosing taken into the coreSPC was
0.4 g/kg× 5 day.
Current IVIG coreSPC indication and dosing:
Guillain–Barré syndrome.
0.4 g/kg/day over 5 days.
No current SCIG coreSPC indication or dosing under discussion.
Recent developments in GBS research
Guillain–Barré syndrome is characterized by several subtypes
(110). The most common form, acute inflammatory demyeli-
nating polyneuropathy (AIDP), is characterized by segmental
demyelination in peripheral nerves with acute flaccid paralysis.
An axonal variant without demyelination either in the form of
acute motor axonal neuropathy (AMAN) or acute motor and sen-
sory axonal neuropathy (AMSAN) have been distinguished from
AIDP. The Miller Fisher syndrome (MFS) variant is defined by
the clinical triad of ophthalmoplegia, areflexia, and ataxia. High
titers of anti-ganglioside IgG auto-antibodies have been described
in GBS: anti-QD1a/Anti-GM1 IgG in AMAN, and Anti-QD1b IgG
in MFS. Antecedent infections (Campylobacter jejuni, Mycoplasma
pneumoniae, or EBV) support the hypothesis of a “carbohydrate
mimicry” driven immunopathogenesis.
N-glycosylation of the Fc-portion of serum IgG was investi-
gated in patients with GBS before and after treatment with IVIG
in relation to clinical course and outcome (111). Treatment-naive
GBS patients compared with age- and sex-matched controls had
lower levels of galactosylation of IgG1 and IgG2. IVIG prepara-
tions contained relatively high levels of galactosylated and sialy-
lated IgG Fc glycoforms compared with serum IgG in patients.
Treatment with IVIG resulted in an increase in serum of the Fc-
galactosylation and -sialylation of both IgG1 and IgG2. Multiple
logistic regression analysis showed that patients with persistent
low-IgG galactosylation and sialylation despite IVIG treatment
had the most severe forms of GBS and needed ventilator support
more often.
Guillain–Barré syndrome normally runs a monophasic disease
course and immunomodulatory treatment is only needed during
the acute phase of the disease. PE and IVIG are both proven to be
equally effective in GBS, while corticosteroids do not confer any
benefit (112–114).
The empirical dose of IVIG is 0.4 g/kg/day for 5 days, which
is based on practice in other autoimmune diseases. In a small,
randomized trial including 39 GBS patients, treatment with
0.4 g/kg/day for 3 or for 6 days was compared. In patients receiv-
ing six treatments, there was a non-significant trend toward a
better outcome. This finding became significant in ventilated
patients (115). In another randomized, open trial with 51 chil-
dren with GBS 1.0 g/kg/day IVIG for 2 days was compared with
0.4 g/kg/day for 5 days, giving the same total dose to each (116).
There were no significant differences in the primary or secondary
outcome measures except that early relapses were significantly
more common after the 2-day (5/23) than the 5-day regimen
(0/23; P = 0.049) In one study, including 50 GBS patients, the total
dose of 2 g/kg was given over 4 days and compared with plasma
exchange. Both treatments were equally effective; IVIG had less
adverse events (108).
Interestingly, the increase in serum IgG (∆IgG) 2 weeks after
IVIG treatment varied considerably (mean 7.8 g/l SD 5.6 g/l).
Patients with low-∆IgG recovered significantly more slowly and
fewer could walk unaided at 6 months (log-rank P < 0.001) (117).
In the latest Cochrane Review of seven trials with a variable
bias risk, IVIG was compared with PE in 623 severely affected
participants. In five trials with 536 participants for whom the
outcome was available, the mean difference of change in a seven-
grade disability scale after 4 weeks was not significantly differ-
ent between the two treatments (118). The authors concluded
that IVIG when started within 2 weeks of disease onset hastens
neurological recovery as much as PE. Adverse events were not
significantly different with either treatment but IVIG was sig-
nificantly more likely to be completed than PE. IVIG following
PE did not provide significant additional benefit. GBS patients
receiving a combination of IVIG and glucocorticosteroids did not
recover faster than patients receiving IVIG alone (119) and adding
mycophenolate mofetil to a combined treatment with IVIG and
corticosteroids did not improve outcomes (120). In a small pilot
study, adding IFN-β1a to IVIG treatment did not contribute to a
better outcome (121).
Various studies have found that IVIG may be superior to PE,
especially in GBS patients with a preceding C. jejuni infection
and GM1 or GM1b auto-antibodies. However, none of these cor-
relations is strong enough to guide therapeutic decisions (122).
Clearly, more dose finding and biomarker research is warranted in
all forms of GBS including pediatric GBS.
CHRONIC INFLAMMATORY DEMYELINATING
POLYRADICULONEUROPATHY
Eight randomized controlled trials (RCT) including 332 CIDP
patients using different IVIG brands and comparing the effects
to either placebo, prednisone or PE showed that IVIG improves
disability short-term, in one large trial the benefit of IVIG per-
sisted for at least 24 weeks (123). Currently, five IVIG products
are licensed for CIDP either purely nationally or via the MR-
procedure in certain EU states or, in one case, centrally in the
entire EU.
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Product specific indication and dosing:
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
For those IVIG products which have the indication CIDP, the dosing
generally consists of a loading dose at 2 g/kg (given over 2–5 days)
followed by maintenance doses of 1 g/kg (given over 1–2 days), cautioning
physicians that the duration of treatment beyond 24 weeks should be
subject to their discretion based upon the patient’s response and
maintenance response in the long-term and further that the dosing and
intervals may have to be adapted according to the individual course of the
disease.
No current IVIG/SCIG coreSPC indication or dosing available.
Recent developments in CIDP research
Chronic inflammatory demyelinating polyneuropathy is an
immune-mediated peripheral nerve disorder characterized by
motor and/or sensory symptoms and signs in more than one limb,
developing over at least 2 months. The disease runs a progres-
sive, relapsing-remitting, or monophasic course and can lead to
significant disability due to walking difficulties and loss of arm
dexterity. A diagnosis relies heavily on electrophysiological studies
that typically show evidence of conduction block and demyelina-
tion. Apart from the typical clinical picture, the EFNS/PNS CIDP
treatment guideline has defined several atypical CIDP phenotypes
of which the pure sensory form is most frequently occurring. The
atypical forms of CIDP may exhibit a different natural course and
treatment response (124).
The key mechanisms in the pathogenesis have not been iden-
tified although several studies have highlighted the role of T-
cells in CIDP and an important role for auto-reactive T-cell
responses against peripheral myelin antigens such as P0, P1,
P2, and peripheral myelin protein (PMP)-22 has been suggested
(125–130).
The short- and midterm efficacy of corticosteroids, IVIG, and
PE has been demonstrated in CIDP in several RCTs and meta-
analyses (131–138). The most recent Cochrane systemic review
(123) analyzed 8 RCTs with a total of 332 eligible patients. The
authors concluded that IVIG improves disability for at least 2–
6 weeks compared with placebo, with a number needed to treat
(NNT) of 3. During this period, it has similar efficacy to PE, oral
prednisolone, and intravenous methylprednisolone. In one large
trial, the benefit of IVIG persisted for 24 and possibly 48 weeks.
Further research is needed to compare the long-term benefits as
well as side effects of IVIG with other treatments (123).
In a recent PK study in 25 CIDP patients with active but sta-
ble disease serum IgG levels before and shortly after serial IVIG
infusions were remarkably constant over time. The change in IgG
levels was associated with IVIG dosage, but not with treatment fre-
quency, and both inter- and intra-patient variability was low. This
indicates that these patients have reached a steady state with a con-
stant distribution rate and turnover of IgG without accumulation
over time. Constant serum IgG levels seem to be required to sta-
bilize CIDP patients (139). A study in two CIDP patients showed
that weekly dosing with IVIG resulted in higher serum IgG trough
levels, which correlated with improved clinical response (140). In a
retrospective cohort study, 15 CIDP patients underwent successful
gradual dose reductions. Most patient started on an initial dose of
2 g/kg/course and could reduce that dose by mean 63% at an aver-
age dose interval of 7 weeks (range of dose reduction: 42.4–88%;
range of treatment frequency: 2–17 weeks). There was high vari-
ability between patients in observed IgG levels (141): the lowest
effective dose of IVIG per course ranged between 18 and 108 g; it
did not correlate to weight, frequency of administration, disease
duration, or pre-therapeutic degree of disability. These results sug-
gest considerably lower, standardized, initiating, and maintenance
doses might be effective and highlight the need for prospective
dose comparative trials (142).
Post-infusion rise in IgG levels (∆IgG) were correlated in indi-
vidual patients (P = 0.005), but inter-patient variability was high
(142). No correlations were ascertained between IgG level vari-
ation and weight, BMI, functional improvement, total dose of
IVIG administered, or dose of IVIG administered per kilogram per
week. Required frequency of IVIG infusions may, however, relate
to patient-specific post-infusion rise of∆IgG levels hence possibly
explaining inter-patient differences in treatment frequency needs.
IgG level monitoring may be helpful in establishing optimum
treatment regimens in individual cases (142).
The highly variable individual IgG doses and treatment inter-
vals were also observed and analyzed by Broyeles et al. (143). The
authors suggested that physicians might be adjusting IgG dosing
in CIDP according to each patient’s clinical condition and treat-
ment response. However, whether these adjustments will optimize
clinical outcome while limiting overall costs has still to be seen.
Not surprising that a Canadian cost-utility study using a Markov
model failed to perceive IVIG as cost-effective treatment for CIDP
compared to corticosteroid treatment (144). A criticism of this
study may be that it was too short to capture all long-term prob-
lems encountered with corticosteroids. On the other hand, IVIG
may be a short-term cost minimizing therapy compared to PE and
in long-term maintenance therapy SCIG has been proven to be
feasible, safe, effective, and cost reducing (145, 146). However, it
should be stated that in Europe no application for a centralized
authorization of a SCIG product in CIDP has as yet been submit-
ted, while several IVIG products are authorized either nationally
or via the MR or DC-procedures in numerous European countries
supporting a class effect of current IVIG brands for the treatment
of CIDP.
Nobile-Orazio et al. (132) compared in a RCT efficacy and tol-
erability of 6 month IVIG vs. IV methylprednisolone (0.5 g/day
on four consecutive days given monthly for 6 months). Treat-
ment of CIDP with IVIG for 6 months was less frequently dis-
continued because of inefficacy, adverse events, or intolerance
than was treatment with IV methylprednisolone. The longer-term
effects of these treatments on the course of CIDP need to be
addressed in future studies, notably as in some patients improve-
ment after corticosteroids seems to be more long-lasting than after
IVIG (124).
Recent RCTs with rituximab (147), intramuscular interferon β-
1a (148), and methotrexate (149) failed to show a beneficial effect
as add-on therapy. In a review by Cocito et al. (150), analyzing
110 patients with refractory CIDP, various immunomodulatory
drugs yielded similarly disappointing results. In contrast, small
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open-label studies investigating mycophenolate mofetil (151) and
alemtuzumab (152) showed promising results on the possibility
to stop or reduce maintenance IVIG therapy.
Better understanding of the pathogenesis is needed to identify
new treatment strategies and to develop biomarkers that corre-
late with disease activity and could help guiding maintenance
treatment in these patients.
MULTIFOCAL MOTOR NEUROPATHY
Since the mid ‘80s MMN was identified as a treatable immune-
mediated disease that responded to cyclophosphamide and IVIG
(153, 154). A Cochrane Review (155) identified a total of 4 RCTs
(including 34 patients) concerning the efficacy and safety of differ-
ent IVIG brands in MMN. These showed that IVIG had a beneficial
effect on strength and a non-significant trend toward improve-
ment of disability. Two further open-label, non-controlled studies
confirmed these results with 1 IVIG product in 20 MMN patients.
Currently, one IVIG product is licensed centrally in the entire
EU; however, some other IVIG products are licensed nation-
ally for MMN, supporting a class effect of current IVIG brands.
Patients with stable clinical course on IVIG conditions can be
safely switched to SCIG at the same monthly dose without risking
deterioration but with an improvement of quality of life (156, 157).
Product specific indication and dosing:
Multifocal Motor Neuropathy (MMN)
In general the starting dose is 2 g/kg for 2–5 days and the maintenance
dose is 1 g/kg every 2–4 weeks or 2 g/kg every 4–8 weeks. IVIG may be
switched to SCIG at the same monthly dose.
No current IVIG/SCIG coreSPC indication or dosing available.
Recent developments in MMN research
Multifocal motor neuropathy is a rare focal inflammatory neu-
ropathy characterized by slowly progressive, asymmetric distal
limb weakness without sensory loss. The hallmark of electro-
physiological examination is a conduction block in the absence
of abnormalities in sensory nerves. Differentiation from amy-
otrophic lateral sclerosis (ALS) and CIDP with asymmetric onset
is important as these diseases differ in prognosis and treatment
(153, 158). The underlying immuno-pathological mechanisms are
unknown but IgM auto-antibodies against ganglioside GM1 and
galactocerebroside GalC are thought to play a role (159).
First treatment option in MMN is IVIG. It improves muscle
strength by 78% and to a lesser extent the disability (39%) in
most patients (153). Corticosteroids, immunosuppressants, or PE
are not effective therapies for MMN, actually these treatments can
even worsen the paresis (158, 160, 161). Optimal dose and intervals
in maintenance treatment have not been established. Evaluating
serum IgG levels in MMN patients receiving a cumulative dose of
2.0 g/kg over 5 days, a wide variation was found in total IgG and
∆IgG levels between patients. Comparing IVIG responders with
non-responders, the ∆IgG levels were higher in the IVIG respon-
ders at each time point (1, 5 days, and 3 weeks after treatment)
with the largest difference on day 1 after IVIG (162). In several
small studies (156, 157, 160), IVIG was switched to SCIG as main-
tenance therapy at the same monthly dose with beneficial results.
An interesting dose-reduction protocol was described by Eftimov
et al. (163) when switching from IVIG to SCIG in 10 stable-phase
MMN patients: 5 received 100% of the IVIG maintenance dose,
the other 5 were put on 50%. All patients in the lower dose group
deteriorated.
In a small randomized trial, mycophenolate mofetil has been
investigated as add-on therapy but did not show any additional
effect over IVIG with placebo (164). Rituximab did not reduce
the need for IVIG in another small open-label study in six MMN
patients (165). Cyclophosphamide especially in combination with
autologous stem cell transplantation has been used in clinical
practice and is recommended in some guidelines for treatment
of refractory patients (160).
MYASTHENIA GRAVIS (MG)
Myasthenia gravis is an autoimmune disease with auto-antibodies
interfering with neuromuscular transmission. Auto-antibodies are
directed to signaling proteins at the neuromuscular junction, in
particular, the nicotinic acetylcholine receptor (AChR). At least
three mechanisms have been proposed to explain how anti-AChR
antibodies compromise neuromuscular transmission: (i) comple-
ment binding and activation at the neuromuscular junction; (ii)
accelerated degradation of AChR molecules (antigenic modula-
tion); and (iii) functional block of AChR-binding sites (166). As
in other autoimmune neuropathies IVIG has been tried as therapy
besides corticosteroid, immunosuppressants, and PE. The results
for IVIG are less convincing than in MMN, CIDP, and GBS and
currently, there is not sufficient solid data to include MG in the
core SPC’s established indications.
Two small trials published in 1984 demonstrated that IVIG
treatment was effective in MG patients at doses of 20 g given
6× over 2 weeks or 1–2 g/kg over 5 days (167). A study in 2005
compared 1 g/kg with 2 g/kg in MG, and found no significant
difference between the two doses for the primary and secondary
endpoints (168).
In the latest Cochrane systematic review, the authors analyzed
all available RCTs (n= 7) differing in inclusion criteria and com-
parator treatment (169). The conclusion of this review is that there
is no evidence from RCTs or from other trials to determine whether
IVIG improves function or reduces the need for steroids.
FETAL NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
Fetomaternal or neonatal alloimmune thrombocytopenia is the
most common cause of severe thrombocytopenia in an otherwise
healthy fetus or neonate. Affected babies are at risk of bleeding,
and ~10–20% (170, 171) may develop intra- and/or extra-uterine
intracranial hemorrhage. In 1988, Bussel and colleagues (172)
described the successful use of a weekly dose of 1 g/kg maternal
weight starting when thrombocytopenia developed in the fetus
until delivery, in seven pregnancies at risk. Meanwhile, several
observational studies have reported on further successful cases
in such affected women (173–176). Based on the results of the
available data, there is no doubt that IVIG (starting between 12
and 20 weeks of gestation) is currently the standard therapy (171,
173, 174, 177). This indication is primarily based on the successful
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prevention of intracranial hemorrhage rather than on increasing
the fetal platelet count. The question whether corticosteroids may
have an additional positive effect in women treated with IVIG
remains open (178).
From a regulatory perspective FNAIT would warrant further
discussion.
Recent developments
Currently, different recombinant monoclonal anti-HPA-1a anti-
bodies, which would be applied in the management of FNAIT,
are under development in murine and translational models (179–
182). In addition, efforts are now being made to establish a
screening program that would help in identifying pregnancies at
risk, and justify the prevention of immunization by vaccination or
neutralization of the antibodies (180, 183).
FETAL HEMOLYTIC DISEASE
Immune antibodies to red blood cell (RBC) antigens can cause sig-
nificant fetal anemia that may occur early in gestation, when fetal
transfusion is difficult to perform. Based on the success observed
in the treatment of FNAIT, IVIG has been used in cases with severe
hemolysis that cannot be compensated by transfusion due to tech-
nical difficulties and/or highly aggressive antibodies. Although,
the results are somewhat conflicting, some benefit was observed
in most cases (184) using a weekly dose of 1 g/kg maternal weight,
commencing from the first trimester. In a recent Cochrane study,
the author’s conclusion was as follows: no information is available
from randomized trials to indicate whether the antenatal use of
IVIG is effective in the management of fetal RBC alloimmuniza-
tion, although several case studies suggest that a beneficial role in
delaying the onset of fetal anemia requiring invasive intrauterine
transfusion (185).
DERMATOLOGICAL DISEASES
Recommendations from the most recent European dermatology
guideline for IVIG use list levels of evidence and grade of recom-
mendations. These recommendations are briefly reiterated here.
IVIGs were deemed to be efficacious in severe forms of dermato-
myositis, polymyositis, and inclusion body myositis (184, 185)
but are usually recommended as second-line therapy. The most
convincing results have been reported in juvenile and adult myosi-
tis patients with acute, potentially life-threatening complications
such as dysphagia, severe weakness, ulcerative skin leasions, and
calcinosis cutis (188, 189). The authors further recommended
IVIG as a second-line treatment in autoimmune blistering dis-
eases, which are relapsing or refractory to standard therapy (190).
In addition, for vasculitic syndromes with a particularly fulmi-
nant progressive disease form with multiple complications and
severe side effects, IVIG therapy may be considered as a first-
line treatment option. Less clear evidence exists for the use of
IVIG in systemic lupus erythematosus. In numerous studies, the
early administration of IVIG in toxic epidermal necrolysis (TEN)
was suggested to be potentially life-saving (evidence level IV, rec-
ommendation grade C). The early administration of high-dose
immunoglobulin should be considered in confirmed cases of TEN
in the absence of any therapeutic alternative (187, 191).
For the various disorders, the authors recommended a dose
of 2 g/kg body weight (3 g/kg in TEN) applied over a period of
2–5 days. For chronic dermatological diseases treatment, intervals
should be every 4 weeks and after 6 months gradually increased to
6-week intervals.
DISCUSSION AND CONCLUSION
Over the last 40 years, the demand of therapeutic Ig has been
steadily increasing worldwide. This has several reasons (i) the
number of indications kept extending from PID and SID into
hematology, neurology, rheumatology, intensive care, and derma-
tology; by now international guidelines list 10–12 high-priority
indications, 15–18 medium priority, and over 20 low-priority
indications. (ii) IVIG is conceived as a safe, well-tolerated, and
well-accepted medicine among patients and doctors explaining
why it has been tried in so many different conditions and helped
surprisingly quite often. (iii) The introduction of a variety of
new preparations (5 and 10% IVIG and 16 and 20% SCIG,
hyaluronidase facilitated SCIG and hyperimmune IVIG) and dif-
ferent routes of application (IV, SC with pump or rapid push,
home treatments) has made the practical therapy more flexible
and easier (8).
It is the purpose of this survey to review critically and to
update indications and dosing strategies of IVIG and SCIG ther-
apies in view of increasing demand, pharmacoeconomic aspects,
and emerging alternatives for the immunomodulatory indications.
Moreover, we wanted to recall the regulatory recommendations
laid down in the core SPC of the European Medicine Agency and
complement this information with current research and develop-
ment data in the field of high-priority IVIG/SCIG replacement or
immunomodulatory therapies.
Dosing of IVIG/SCIG in PAD replacement therapy no longer
relies on fixed monthly doses but rather on a treat-to-target strat-
egy the goal being a maximal reduction and control of bacterial
infectious episodes and avoidance of side effects. Thus, monthly
dosage, route of administration (IV or SC), infusion intervals and
serum Ig levels are secondary to this goal but have to be opti-
mized for the individual patient in order to reach the best possible
result (24). The flexibility to comply with patients’ needs has been
greatly improved. Not only can the same total weekly SCIG dose
be administered at different intervals, from daily to biweekly (to
monthly for the facilitated SCIG), with minimal impact on serum
IgG levels (21, 22), SCIG and IVIG may also be applied in an
alternating mode to increase convenience and quality of life (23).
Several SCIG loading regimens rapidly achieve adequate serum
IgG levels in treatment-naïve patients (22). There is reasonable
evidence to calculate the loading dose on ideal body-weight (2, 3)
and to increase monthly dosages by 0.15 g/kg until break-through
infections are sufficiently controlled (17). Infusion-related reac-
tions can be avoided or minimized in most cases by switching
from IVIG to SCIG. While the FDA recommends the use of a DAC
when switching from IVIG to SCIG (6, 7) the European experi-
ence reports satisfactory results by just maintaining the monthly
IVIG dose and dividing it in weekly, biweekly, or even smaller doses
(192). It is now generally accepted that Ig replacement therapy does
more than just replace the antibody repertoire in PAD patients
(30). It also serves as a biological response modifier with anti-
inflammatory properties (31, 32) that contribute to the clinical
benefit of IVIG/SCIG therapy in immunodeficient patients. The
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bottom line of the current knowledge on Ig replacement therapy
is optimizing the results by individualizing the treatment regi-
mens; recently, this principle has been beautifully illustrated by
case studies from Bonagura (20).
Regarding the major immunomodulatory indications for IVIG,
it is striking how little evidence and structure has so far been
brought into the dosing issue. Most studies still start with the
2 g/kg protocol (preferably given on 1 single day, instead of being
spread over 5 days), as originally described in the ITP (71, 72) and
KD (87, 88) trials. Although a down-scaling regime in ITP showed
that 1 g/kg was as efficient as 2 g/kg (72), it was the latter dose that
set the stage for the regulatory adoption of the dosage regimen in
ITP and other “immunomodulatory settings” for years to come.
There are only a few case reports dictated by economic constraints
suggesting that lower doses (0.1–0.4 g/kg) may also exhibit effec-
tive immunomodulatory activity (77, 78) but no systematic dose
exploration has been performed. Especially no up-scaling dosage
regimen has been pursued as in Ig replacement therapy for PAD
patients (17). Down-scaling attempts (141, 142) and a trend to
switch from IVIG to SCIG have been made in chronic diseases
such CIDP (145, 146) and MMN (156, 157, 160, 163). In the acute
phases of GBS or in myasthenic crisis comparative studies between
PE and IVIG showed equal effectiveness but advantages for IVIG
with respect to feasibility and costs. Despite much effort that has
been put into the analysis of mechanisms governing responsive-
ness and non-responsiveness to high-dose IVIG in ITP, KD, and the
neuroimmunological indications no clear-cut picture has emerged
so far (186). Some biomarkers, however, may be helpful to iden-
tify responders from non-responders and thereby try early on
alternative treatment options (94–96, 111). Driven by the need
to be cost-effective the pursuit of alternative treatment options
is another strong trend in many studies on immunomodulatory
IVIG indications. Thus, the renaissance of corticosteroids in the
long-term treatment of KD (97, 103–105) and CIDP (132, 135) are
examples. A recent overview of immunological treatment options
in neuroimmunological emergencies by von Geldern et al. (193)
nicely illustrates that IVIG is only one among several treatment
choices, although a very important and effective one.
Clearly, more research is needed to clarify the mode of action
of IVIG in immunomodulation and to optimize dosing and
treatment intervals.
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